[1]封海梅,黄亚迪,许可,等.Ybox结合蛋白1在人结肠癌中的表达及其与预后的关系[J].医学研究与战创伤救治(原医学研究生学报),2026,39(01):37-44.[doi:10.16571/j.cnki.20972768.2026.01.006]
　FENG Haimei,HUANG Yadi,XU Ke,et al.Expression of YBX1 in human colon cancer and its relationship with patient prognosis[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2026,39(01):37-44.[doi:10.16571/j.cnki.20972768.2026.01.006]
点击复制

Ybox结合蛋白1在人结肠癌中的表达及其与预后的关系()

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第39卷
期数:
2026年01期
页码:
37-44
栏目:
临床研究
出版日期:
2026-01-20

文章信息/Info

Title:
Expression of YBX1 in human colon cancer and its relationship with patient prognosis
作者:
封海梅1; 黄亚迪2; 许可3; 雷增杰1; 3; 褚晓源1; 3
南京中医药大学金陵临床医学院（东部战区总医院）肿瘤内科，江苏南京 210002
Author(s):
FENG Haimei1;  HUANG Yadi2;  XU Ke3;  LEI Zengjie1; 3;  CHU Xiaoyuan1; 3
Department of Oncology, Jinling Clinical Medical College, Nanjing University of Chinese Medicine/General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China
关键词:
结肠癌; Ybox结合蛋白1; 转录因子; 预后; 迁移能力
Keywords:
colon cancer;  Ybox binding protein 1;  transcription factor;  prognosis;  migratory capacity
分类号:
R735.3
DOI:
10.16571/j.cnki.20972768.2026.01.006
文献标志码:
A
摘要:
目的探讨Ybox结合蛋白1（YBX1）在结肠癌中的表达及其对结肠癌患者预后的影响，探索YBX1对结肠癌细胞迁移能力的影响。方法分析癌症基因组图谱（TCGA）数据库中YBX1在结肠癌中的mRNA表达水平。通过实时荧光定量PCR方法（qRTPCR）和蛋白质免疫印迹（Western blot）方法及免疫组化方法分别检测YBX1在结肠癌组织和细胞中的mRNA和蛋白表达量。67例结肠癌患者的肿瘤组织及癌旁组织经免疫组化染色方法分析YBX1蛋白表达，并分析患者临床特征和预后的关系，采用Cox比例风险回归模型分析结肠癌预后的影响因素。根据处理方式不同分为Mock组（用不含病毒的空载体溶液处理细胞）、NC组（无靶向作用的shRNA处理细胞）、LvYBX1组（过表达YBX1）、sh1YBX1组及sh2YBX1组（分别通过慢病毒载体携带的sh1YBX1 RNA、sh2YBX1 RNA，使细胞敲低YBX1基因的表达）。通过划痕实验与Transwell实验检测YBX1对结肠癌细胞迁移能力的影响。结果TCGA数据库样本分析显示，结肠腺癌YBX1的mRNA及蛋白表达水平显著高于癌旁组织（P<0.05）。qRTPCR分析显示，肿瘤组织中YBX1的mRNA表达水平显著高于邻近正常组织（P<0.01）。免疫组化结果及评分显示，YBX1在结肠癌组织中高表达（12.60±2.03），在癌旁组织中低表达（4.24±0.56），差异具有统计学意义（P<0.01）。KaplanMeier生存曲线结果显示，高表达YBX1的患者OS、DFS较低表达YBX1的患者明显降低（P<0.05）。在HCT15、HCT8细胞系中，与NC组相比，LvYBX1组的蛋白及mRNA水平明显升高（P<0.05）。在CACO2、SW480细胞系中，与NC组相比，sh1YBX1、sh2YBX1组的蛋白及mRNA水平明显降低（P<0.05）。与NC组相比，LvYBX1组HCT15与HCT8细胞的迁移能力均显著增强（P<0.05），sh1YBX1、sh2YBX1组CACO2与SW480细胞的迁移能力均显著降低（P<0.05）。结论YBX1高表达是结肠癌患者不良预后的危险因素，YBX1可作为结肠癌患者疾病进展及预后的潜在标志物。
Abstract:
ObjectiveThe study investigated the expression of Ybox binding protein 1 (YBX1) in colon cancer and its effect on the prognosis of colon cancer patients, and explored the effect of YBX1 on the migration ability of colon cancer cells. MethodsThe expression level of YBX1 mRNA in colorectal cancer was analyzed using the Cancer Genome Atlas (TCGA) database. The mRNA and protein expression of YBX1 in colon cancer tissues and cells were detected by realtime fluorescence quantitative PCR (qRTPCR) and protein immunoblotting (Western blot) methods and immunohistochemistry. The tumor tissues and adjacent cancer tissues of 67 colon cancer patients were analyzed for YBX1 protein expression using immunohistochemical staining. The relationship between patients′ clinical characteristics and prognosis was analyzed and Cox proportional hazards regression model was used to analyze prognostic factors of colorectal cancer. Cells were divided into four groups based on treatment methods: the Mock group (cells treated with an empty vector solution without virus), the NC group (cells treated with nontargeted shRNA), the LvYBX1 group (YBX1 overexpression group), the sh1YBX1 group (YBX1 knockdown group 1), and the sh2YBX1 group (YBX1 knockdown group 2). The effects of YBX1 on the migration ability of colon cancer cells were examined by scratch assay and Transwell assay.ResultsAnalysis of samples from the TCGA database revealed that mRNA and protein expression levels of YBX1 in colorectal adenocarcinoma were significantly higher than in adjacent noncancerous tissue. qRTPCR analysis showed that the mRNA expression level of YBX1 in tumor tissues was significantly higher than that in adjacent normal tissues (P<0.01). Immunohistochemical results and scoring showed that YBX1 was highly expressed in colon cancer tissues (12.60±2.03) and lowly expressed in adjacent normal tissues (4.24±0.56), with a statistically significant difference (P<0.01). KaplanMeier survival curve results showed that patients with high YBX1 expression had significantly lower overall survival (OS) and diseasefree survival (DFS) than those with low YBX1 expression (P<0.05). In the HCT15 and HCT8 cell lines, compared with the NC group, the protein and mRNA levels in the LvYBX1 group were significantly increased (P<0.05). In the CACO2 and SW480 cell lines, compared with the NC group, the protein and mRNA levels in the sh1YBX1 and sh2YBX1 groups were significantly decreased (P<0.05). Compared with the NC group, the migration ability of HCT15 and HCT8 cells in the LvYBX1 group was significantly enhanced (P<0.05), while the migration ability of CACO2 and SW480 cells in the sh1YBX1 and sh2YBX1 groups was significantly decreased (P<0.05).ConclusionHigh expression of YBX1 is a risk factor for poor prognosis in colorectal cancer patients, and YBX1 can serve as a potential biomarker for disease progression and prognosis in colorectal cancer patients.

参考文献/References:

[1]张林杰,代海涛,王亚,等.口腔鳞状细胞癌中SUFU的表达水平及其对细胞生物学行为的影响[J].医学研究与战创伤救治,2024,37(6):561566.[2]Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229263. [3]Chang L, Jung NY, Atari A, et al. Systematic profiling of conditional pathway activation identifies contextdependent synthetic lethalities[J]. Nat Genet, 2023, 55(10): 17091720. [4]Gross P. Defining genome access of transcription factors[J]. Nat Genet, 2024，56(10):1999.[5]Goodarzi H, Liu X, Nguyen HC, et al. Endogenous tRNADerived Fragments Suppress Breast Cancer Progression via YBX1 Displacement[J]. Cell, 2015, 161(4): 790802. [6]Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5): 646674. [7]Heichler C, Scheibe K, Schmied A, et al. STAT3 activation through IL6/IL11 in cancerassociated fibroblasts promotes colorectal tumour development and correlates with poor prognosis[J]. Gut, 2020, 69(7): 12691282. [8]Hossain MS, Karuniawati H, Jairoun AA, et al. Colorectal Cancer: A Review of Carcinogenesis, Global Epidemiology, Current Challenges, Risk Factors, Preventive and Treatment Strategies[J]. Cancers (Basel), 2022, 14(7):1732. [9]Jayavelu AK, Schnder TM, Perner F, et al. Splicing factor YBX1 mediates persistence of JAK2mutated neoplasms[J]. Nature, 2020, 588(7836): 157163. [10]Shay JES, Yilmaz H. Dietary and metabolic effects on intestinal stem cells in health and disease[J]. Nat Rev Gastroenterol Hepatol, 2024，22(1):2338. [11]Liu L, Chen Y, Zhang T, et al. YBX1 Promotes Esophageal Squamous Cell Carcinoma Progression via m5CDependent SMOX mRNA Stabilization[J]. Adv Sci (Weinh), 2024, 11(20): e2302379. [12]Li C, Wang W, Sun Y, et al. Selective sorting and secretion of hY4 RNA fragments into extracellular vesicles mediated by methylated YBX1 to promote lung cancer progression[J]. J Exp Clin Cancer Res, 2022, 41(1): 136. [13]Vabi BW, Gibbs JF, Parker GS. Implications of the growing incidence of global colorectal cancer[J]. J Gastrointest Oncol, 2021, 12(Suppl 2): S387S398. [14]地里呼玛尔·吐鲁洪,王少华.转录因子RFX1上调FZD2促进乳腺癌增殖、侵袭和转移[J].东南国防医药,2023,25(3):230236.[15]Wang L, Zhu Y, Zhang N, et al. The multiple roles of interferon regulatory factor family in health and disease[J]. Signal Transduct Target Ther, 2024, 9(1): 282. [16]Wang Y, Jia J, Wang F, et al. Premetastatic niche: formation, characteristics and therapeutic implication[J]. Signal Transduct Target Ther, 2024, 9(1): 236.

相似文献/References:

[1]吴 曼,骆文香,崔向华,等.结肠癌宫颈转移1例[J].医学研究与战创伤救治(原医学研究生学报),2012,14(01):26.
[2]张胜行,张诗兰,兰小鹏.人结肠癌SW480细胞裸鼠皮下移植瘤模型的建立[J].医学研究与战创伤救治(原医学研究生学报),2012,14(02):108.
　ZHANG Sheng-hang,ZHANG Shi-lan,LAN Xiao-peng..The establishment of a subcutaneously transplanted tumor model with human colon cancer cell line SW480 in nude mice[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2012,14(01):108.
[3]梁 冲,王跃华,李增才,等.氟尿嘧啶缓释剂在老年结肠癌术后疗效的观察[J].医学研究与战创伤救治(原医学研究生学报),2010,12(04):299.
　LIANG Chong,WANG Yue-hua,LI Zeng-cai,et al.Research on implanting of 5-Fluorouracil sustained-release to prevent local recurrence of colon carcinomas in the old[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2010,12(01):299.
[4]张胜行,兰小鹏,易浔飞.靶向DcR3的siRNA抑制人结肠癌 裸鼠皮下移植瘤的实验研究[J].医学研究与战创伤救治(原医学研究生学报),2009,11(01):1.
　ZHANG Sheng-hang,LAN Xiao-peng,Yi Xun-Fei.Colon cancer subcutaneously inoculated in nude mice inhibited by siRNA to DcR3[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(01):1.
[5]陆春雷,吴国忠,尹天泉,等.细胞粘附在结肠癌细胞系SW480多药耐药表型中的作用[J].医学研究与战创伤救治(原医学研究生学报),2009,11(06):485.
　LU Chun-lei,WU Guo-zhong,YIN Tian-quan,et al.Roles of cell adhesion in multidrug resistance phenotype of colon cancer cell line SW480[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2009,11(01):485.
[6]冒晓蓓,刘小北,褚晓源,等.叉头框蛋白M1、环氧合酶2在结肠癌组织中的表达及相关性分析[J].医学研究与战创伤救治(原医学研究生学报),2014,16(03):225.[doi:10.3969/j.issn.1672-271X.2014.03.001]
　MAO Xiao-bei,LIU Xiao-bei,CHU Xiao-yuan,et al.Expression and correlation of FoxM1 and COX-2 in colorectal cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2014,16(01):225.[doi:10.3969/j.issn.1672-271X.2014.03.001]

备注/Memo

备注/Memo:
基金项目：国家自然科学基金（82072725，81702442）
更新日期/Last Update: 2026-03-02